Rentschler Biopharma SE, a global contract development and manufacturing organisation (CDMO) for biopharmaceuticals, has appointed Patrick Cushing, as the Vice President of Operations for Rentschler Biopharma, Inc., the company’s US subsidiary. This change will be effective May 1, 2024.
In this newly created position, Dr Cushing will oversee and manage all operational processes at the site and report to Rentschler Biopharma’s Chief Operating Officer, Christiane Bardroff.
Christiane Bardroff, Chief Operating Officer at Rentschler Biopharma, commented: “The creation of this new position recognises many important milestones we have achieved during the last months, with new manufacturing lines coming online at our US facility. Patrick brings exceptional leadership skills to this role, having consistently demonstrated his ability to work not only with his team and across departments but also with colleagues from other Rentschler Biopharma sites. In his new role, he will serve to further streamline and strengthen the organisation as we support existing and new clients in the US”
Patrick Cushing joined Rentschler Biopharma in 2021 and has served as Senior Director of Manufacturing Operations at the company’s site in Milford, MA, demonstrating managerial capabilities in biopharmaceuticals, cultivated through leadership roles in contract research and contract manufacturing organisations.
With over a decade of experience in structure-based drug discovery and large molecule process development, Patrick has been instrumental in enhancing Chemistry, Manufacturing and Controls (CMC) processes.
His expertise spans the development of diverse molecules, from plasmid DNA to recombinant proteins, including complex biologics such as challenging proteins, bispecific antibodies, enzymes and protein complexes.
